Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEO21-RS
ISRCTN11264442Phase 2Suspended
- Sponsor
- University of Liverpool
- Start
- Sep 2019
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, open-label trial of palbociclib in breast cancer (4 arms), sponsored by University of Liverpool. Primary endpoint: Change in Ki67 proliferation marker. Started Sep 2019; status: suspended.
02
Drugs
palbociclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on ISRCTN11264442.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN11264442.